A study of DPM-1003
Latest Information Update: 22 Mar 2024
At a glance
- Drugs DPM-1003 (Primary)
- Indications Rett syndrome
- Focus Adverse reactions
Most Recent Events
- 19 Mar 2024 According to a DepYmed media release, company announced that it has received clearance from the U.S. Food and Drug Administration to initiate its phase 1 clinical trial for DPM-1003 for the treatment of Rett Syndrome.
- 07 Jun 2023 New trial record
- 31 May 2023 According to a DepYmed media release, company plans initiate a Phase 1 clinical trial in 2024